Nuvation Bio, Inc.(NUVB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NUVB Nuvation Bio, Inc.

Pre-Mkt 03-31 06:21:25 EDT

4.05

-0.20

-4.71%

盘前4.24

+0.19+4.69%

06:16 EDT

High4.32	Low4.05	Vol3.55M
Open4.25	D1 Closing4.25	Amplitude6.35%
Mkt Cap1.41B	Tradable Cap935.74M	Total Shares347.60M
T/O14.69M	T/O Rate1.53%	Tradable Shares231.05M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NUVB","market":"US","secType":"STK","nameCN":"Nuvation Bio, Inc.","latestPrice":4.05,"timestamp":1774900800000,"preClose":4.25,"halted":0,"volume":3546446,"hourTrading":{"tag":"盘前","latestPrice":4.24,"preClose":4.05,"latestTime":"06:16 EDT","volume":2,"amount":8.48,"timestamp":1774952186660,"change":0.19,"changeRate":0.046914,"amplitude":0},"delay":0,"changeRate":-0.047058823529411806,"floatShares":231046340,"shares":347597289,"eps":-0.6,"marketStatus":"Pre-Mkt","change":-0.2,"latestTime":"03-31 06:21:25 EDT","open":4.25,"high":4.315,"low":4.045,"amount":14693383.269534001,"amplitude":0.063529,"askPrice":4.61,"askSize":91,"bidPrice":3.35,"bidSize":123,"shortable":3,"etf":0,"ttmEps":-0.6,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1774963800000},"marketStatusCode":1,"adr":0,"exchange":"NYSE","adjPreClose":4.05,"preHourTrading":{"tag":"盘前","latestPrice":4.24,"preClose":4.05,"latestTime":"06:16 EDT","volume":2,"amount":8.48,"timestamp":1774952186660,"change":0.19,"changeRate":0.046914,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":4.0281,"preClose":4.05,"latestTime":"19:57 EDT","volume":61934,"amount":251205.4487,"timestamp":1774915049498,"change":-0.0219,"changeRate":-0.005407,"amplitude":0.024691},"volumeRatio":1.086963224588964,"impliedVol":2.135,"impliedVolPercentile":0.952},"requestUrl":"/m/hq/s/NUVB","defaultTab":"news","newsList":[{"id":"2622824632","title":"Nuvation Bio (NUVB) Receives a Buy from Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2622824632","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622824632?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:56","pubTimestamp":1774616178,"startTime":"0","endTime":"0","summary":"Wedbush analyst David Nierengarten maintained a Buy rating on Nuvation Bio today and set a price target of $11.00. Nierengarten covers the Healthca...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/nuvation-bio-nuvb-receives-a-buy-from-wedbush-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/nuvation-bio-nuvb-receives-a-buy-from-wedbush-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622821175","title":"Nuvation Bio Price Target Maintained With a $11.00/Share by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2622821175","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622821175?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:47","pubTimestamp":1774615620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NUVB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 27, 2026 08:47 ET (12:47 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622232878","title":"March 2026's Promising Penny Stocks To Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2622232878","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622232878?lang=en_us&edition=fundamental","pubTime":"2026-03-27 19:05","pubTimestamp":1774609510,"startTime":"0","endTime":"0","summary":"Over the last 7 days, the market has dropped 1.6%, but it remains up by 15% over the past year, with earnings expected to grow by 16% annually. In such a climate, identifying stocks with solid financial health can be crucial for investors looking for growth opportunities. Penny stocks—often associated with smaller or newer companies—still hold potential when they demonstrate financial strength and long-term promise.","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/march-2026s-promising-penny-stocks-to-watch","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/march-2026s-promising-penny-stocks-to-watch","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2362541273.HKD","SG9999006266.SGD","LU1242518857.USD","BK4230","LU1839390173.USD","SGXZ58947870.SGD","SIGA","BK4122","LU0441851309.USD","BK4076","LU0532188223.SGD","BK4183","LU2362540622.SGD","LU2125910500.SGD","BK4142","LU2045819591.USD","TOUR","BK4503","BK4007","GRAB","BK4125","LU1242518931.SGD","LFVN","NAGE","LU0979878070.USD","LU2362541513.USD","LU1046422090.SGD","SG9999002620.SGD","BK4531","BK4579","LU0049112450.USD","NUVB","SG9999001135.SGD","SG9999002406.SGD","SG9999013486.USD","LU1235295612.USD","BK4191","BK4134","BK4583","III","RERE","CRCT","SG9999013478.USD",".IXIC","SG9999002604.SGD","SG9999002414.USD","BK4022","FINV","BK4166","BK4539","SSP","LX","BK4121","SG9999013460.SGD","SG9999002679.SGD","LU0210637038.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622789607","title":"Nuvation Bio and Eisai’s MAA for taletrectinib in NSLC accepted in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2622789607","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622789607?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:10","pubTimestamp":1774555815,"startTime":"0","endTime":"0","summary":"Nuvation Bio (NUVB) and Eisai Co. (ESAIY) announced that the European Medicines Agency, or EMA, has validated the Marketing Authorisation Applicati...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nuvation-bio-and-eisais-maa-for-taletrectinib-in-nslc-accepted-in-europe-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nuvation-bio-and-eisais-maa-for-taletrectinib-in-nslc-accepted-in-europe-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ESAIY","NUVB","MAA","BK4585","BK4007","BK4215","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622896493","title":"Nuvation Bio shares rise; EMA validates taletrectinib MAA for advanced ROS1+ NSCLC in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2622896493","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622896493?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:09","pubTimestamp":1774555796,"startTime":"0","endTime":"0","summary":"The European Medicines Agency validated and accepted for review a Marketing Authorisation Application for taletrectinib to treat advanced ROS1+ non-small cell lung cancer.Eisai and Nuvation Bio said the application will follow a standard review timeline.Taletrectinib is already approved in the US, China, and Japan for advanced ROS1+ non-small cell lung cancer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL5fGNPK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622896452","title":"Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced Ros1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency","url":"https://stock-news.laohu8.com/highlight/detail?id=2622896452","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622896452?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:08","pubTimestamp":1774555693,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nFWN40E14Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620272091","title":"Is It Time To Reassess Nuvation Bio (NUVB) After Its Recent Share Price Swings?","url":"https://stock-news.laohu8.com/highlight/detail?id=2620272091","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620272091?lang=en_us&edition=fundamental","pubTime":"2026-03-20 07:09","pubTimestamp":1773961755,"startTime":"0","endTime":"0","summary":"If you are trying to work out whether Nuvation Bio is attractively priced or not, the recent share performance gives you some useful starting clues.\nAt a last close of US$4.26, the stock has seen a 2.5% decline over the past week and a 27.6% decline over the past month, but is up 117.3% over 1 year and 156.6% over 3 years. Over 5 years, the return sits at a 59.4% decline.\nThis mix of shorter term weakness and longer term strength has put valuation in sharper focus for many investors. With...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/is-it-time-to-reassess-nuvation-bio-nuvb-after-its-recent-sh","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/is-it-time-to-reassess-nuvation-bio-nuvb-after-its-recent-sh","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620340368","title":"Nuvation Bio to present updated IBTROZI trial data at AACR Annual Meeting 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620340368","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620340368?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:36","pubTimestamp":1773779764,"startTime":"0","endTime":"0","summary":"Nuvation Bio said it will attend the AACR Annual Meeting 2026 in San Diego, California, running April 17-22, 2026. An oral presentation on updated TRUST-I and TRUST-II data for taletrectinib in TKI-nave ROS1+ NSCLC is scheduled for April 21, 2026, from 2:30-4:30 p.m. PST. Two poster presentations are also scheduled for April 21, 2026, from 2:00-5:00 p.m. PST, covering taletrectinib data in TKI-pretreated ROS1+ NSCLC and ROS1 fusion models.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief via PR Newswire  on March 17, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDLtJZLv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620240352","title":"Nuvation Bio to present TRUST-I and TRUST-II taletrectinib data showing 50-month median response duration in TKI-naïve ROS1+ NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2620240352","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620240352?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:35","pubTimestamp":1773779739,"startTime":"0","endTime":"0","summary":"Nuvation Bio to present TRUST-I and TRUST-II taletrectinib data showing 50-month median response duration in TKI-nave ROS1+ NSCLC. Nuvation Bio said updated results from the Phase 2 TRUST-I and TRUST-II studies of IBTROZI  in advanced ROS1-positive non-small cell lung cancer will be presented at the AACR Annual Meeting 2026. In tyrosine kinase inhibitor -nave patients, the company reported a median duration of response of 50 months based on an August 2025 data cutoff. An oral presentation of the TKI-nave dataset is scheduled for April 21, 2026, led by Lyudmila Bazhenova. Updated efficacy and safety data in TKI-pretreated patients will be presented in a poster session on April 21, 2026, led by Geoffrey Liu.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDLW31ys:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618256249","title":"A Look At Nuvation Bio (NUVB) Valuation After Its 2025 Results Show Revenue Growth And A Narrowed Net Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2618256249","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618256249?lang=en_us&edition=fundamental","pubTime":"2026-03-11 21:23","pubTimestamp":1773235421,"startTime":"0","endTime":"0","summary":"Nuvation Bio (NUVB) just paired its latest earnings report with a new shelf registration filing, putting both its recent revenue profile and future capital raising options in sharper focus for anyone tracking the stock.\nSee our latest analysis for Nuvation Bio.\nThe latest earnings update and shelf registration come after a mixed share price run, with a recent 7 day share price return of 7.57% but a 90 day share price return decline of 40.18%. Despite that weaker near term momentum, the 1 year...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/a-look-at-nuvation-bio-nuvb-valuation-after-its-2025-results","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/a-look-at-nuvation-bio-nuvb-valuation-after-its-2025-results","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616511535","title":"Nuvation Bio falls -25.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616511535","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616511535?lang=en_us&edition=fundamental","pubTime":"2026-03-04 23:08","pubTimestamp":1772636919,"startTime":"0","endTime":"0","summary":"Nuvation Bio (NUVB) is down -25.3%, or -$1.48 to $4.36. Published first on TheFly – the ultimate source for real-time, market-moving breaking finan...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nuvation-bio-falls-25-3-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nuvation-bio-falls-25-3-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616586735","title":"Nuvation Bio’s Taletrectinib Outlook Clouded by Commercialization and Partner Execution Risks","url":"https://stock-news.laohu8.com/highlight/detail?id=2616586735","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616586735?lang=en_us&edition=fundamental","pubTime":"2026-03-04 14:00","pubTimestamp":1772604055,"startTime":"0","endTime":"0","summary":"Nuvation Bio Inc (NUVB) has disclosed a new risk, in the Sales & Marketing category. Nuvation Bio Inc. faces significant commercialization risk if ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nuvation-bios-taletrectinib-outlook-clouded-by-commercialization-and-partner-execution-risks?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nuvation-bios-taletrectinib-outlook-clouded-by-commercialization-and-partner-execution-risks?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112719418","title":"Stock Track | Nuvation Bio Soars 5.50% in Post-Market on Positive Analyst Ratings and Maintained Buy Recommendations","url":"https://stock-news.laohu8.com/highlight/detail?id=1112719418","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112719418?lang=en_us&edition=fundamental","pubTime":"2026-03-04 09:50","pubTimestamp":1772589059,"startTime":"0","endTime":"0","summary":"Nuvation Bio Inc. (NUVB) experienced a significant surge of 5.50% during post-market trading on Tuesday, reflecting positive investor sentiment following recent analyst actions.The stock's upward...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616137686","title":"Nuvation Bio Is Maintained at Neutral by UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2616137686","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616137686?lang=en_us&edition=fundamental","pubTime":"2026-03-04 03:27","pubTimestamp":1772566020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NUVB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 03, 2026 14:27 ET (19:27 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616327706","title":"Nuvation Bio Plunges on Higher Discontinuations in Ibtrozi Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2616327706","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616327706?lang=en_us&edition=fundamental","pubTime":"2026-03-04 01:13","pubTimestamp":1772557980,"startTime":"0","endTime":"0","summary":"Shares of Nuvation Bio fell after the oncology company said early sales of Ibtrozi, a lung-cancer drug that represents its only source of product revenue, showed a high rate of discontinuations.The stock tumbled 26%, to $4.33, midday Tuesday. The stock has gained nearly one-and-a-half times its value in the past year.Chief Commercial Officer Colleen Sjogren told analysts on a Monday call that three-quarters of Ibtrozi discontinuations from patients in the company's Nuvation Connect support program came from later-line populations.She said it isn't unusual that the majority of patients early in an oncology launch are in need of a third or fourth medicine, which translates to a lower response and duration of treatment. Dicontinuations are expected to fall as the company moves Ibtrozi further up in the treatment paradigm, she said.\"By the end of 2026, we expect to see a more direct correlation between growth in new patient starts and growth in our revenue, as a larger portion of active pa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Nuvation Bio Plunges on Higher Discontinuations in Ibtrozi Launch","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616090322","title":"Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (SRRK) and Nuvation Bio (NUVB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616090322","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616090322?lang=en_us&edition=fundamental","pubTime":"2026-03-04 00:30","pubTimestamp":1772555412,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Scholar Rock Holding (SRRK – Research Report) and Nu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-scholar-rock-holding-srrk-and-nuvation-bio-nuvb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-scholar-rock-holding-srrk-and-nuvation-bio-nuvb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","BK4581","BK4007","LU0029874061.USD","LABU","XBI","LU0128526141.USD","BK4588","BK4137","BK4585","BK4139","HCSG","SRRK","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616210173","title":"Nuvation Bio falls -26.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616210173","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616210173?lang=en_us&edition=fundamental","pubTime":"2026-03-03 23:06","pubTimestamp":1772550412,"startTime":"0","endTime":"0","summary":"Nuvation Bio (NUVB) is down -26.1%, or -$1.52 to $4.32. Published first on TheFly – the ultimate source for real-time, market-moving breaking finan...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nuvation-bio-falls-26-1-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nuvation-bio-falls-26-1-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180923020","title":"Stock Track | Nuvation Bio Plummets 25.26% Intraday on Earnings Miss and Analyst Downgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=1180923020","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180923020?lang=en_us&edition=fundamental","pubTime":"2026-03-03 22:44","pubTimestamp":1772549076,"startTime":"0","endTime":"0","summary":"Nuvation Bio Inc. (NUVB) shares plummeted 25.26% during intraday trading on Tuesday, marking a significant decline for the biotechnology stock.The sharp drop follows the company's recent...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616362328","title":"RBC Raises Price Target on Nuvation Bio to $13 From $12, Keeps Outperform, Speculative Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2616362328","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616362328?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:57","pubTimestamp":1772542679,"startTime":"0","endTime":"0","summary":"Nuvation Bio (NUVB) has an average rating of buy and mean price target of $11.60, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616347777","title":"Truist Financial Keeps Their Buy Rating on Nuvation Bio (NUVB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616347777","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616347777?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:37","pubTimestamp":1772541468,"startTime":"0","endTime":"0","summary":"Truist Financial analyst Gregory Renza reiterated a Buy rating on Nuvation Bio today and set a price target of $12.00. Renza covers the Healthcare ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/truist-financial-keeps-their-buy-rating-on-nuvation-bio-nuvb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/truist-financial-keeps-their-buy-rating-on-nuvation-bio-nuvb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NUVB"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.069},{"period":"1month","weight":-0.3147},{"period":"3month","weight":-0.547},{"period":"6month","weight":0.0946},{"period":"1year","weight":1.2253},{"period":"ytd","weight":-0.548}],"compareEarnings":[{"period":"1week","weight":-0.0357},{"period":"1month","weight":-0.0787},{"period":"3month","weight":-0.0801},{"period":"6month","weight":-0.0546},{"period":"1year","weight":0.1373},{"period":"ytd","weight":-0.0732}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung , M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco .","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.099824},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.044723},{"month":3,"riseRate":0.5,"avgChangeRate":0.077046},{"month":4,"riseRate":0.4,"avgChangeRate":0.005292},{"month":5,"riseRate":0.6,"avgChangeRate":0.002702},{"month":6,"riseRate":0.2,"avgChangeRate":-0.090917},{"month":7,"riseRate":0.6,"avgChangeRate":0.065913},{"month":8,"riseRate":0.6,"avgChangeRate":0.013694},{"month":9,"riseRate":0.5,"avgChangeRate":-0.038205},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.016548},{"month":11,"riseRate":0.5,"avgChangeRate":0.163132},{"month":12,"riseRate":0.666667,"avgChangeRate":0.061496}],"exchange":"NYSE","name":"Nuvation Bio, Inc.","nameEN":"Nuvation Bio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nuvation Bio, Inc.(NUVB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nuvation Bio, Inc.(NUVB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nuvation Bio, Inc.,NUVB,Nuvation Bio, Inc.股票,Nuvation Bio, Inc.股票老虎,Nuvation Bio, Inc.股票老虎国际,Nuvation Bio, Inc.行情,Nuvation Bio, Inc.股票行情,Nuvation Bio, Inc.股价,Nuvation Bio, Inc.股市,Nuvation Bio, Inc.股票价格,Nuvation Bio, Inc.股票交易,Nuvation Bio, Inc.股票购买,Nuvation Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nuvation Bio, Inc.(NUVB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nuvation Bio, Inc.(NUVB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}